# Acacia Pharma

Source: https://onco.cc/companies/acacia-pharma/  
OnCo record `acacia-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Acacia Pharma was a Cambridge company that repurposed the old antipsychotic amisulpride, at low dose, to prevent and treat nausea and vomiting after surgery and chemotherapy; it was bought by Eagle Pharmaceuticals in 2022.

## Summary

Acacia Pharma, founded in 2007 in Cambridge, England, developed intravenous low-dose amisulpride (Barhemsys) for postoperative nausea and vomiting, approved by the FDA in 2020, and tested the same drug (APD403) in phase 3 for chemotherapy-induced nausea and vomiting. Eagle Pharmaceuticals acquired the company in 2022. Its trials remain on ClinicalTrials.gov under Acacia as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Acacia Pharma Ltd; Acacia Pharma Group
- Tags: ctgov-sponsor
- HQ: Cambridge
- Type: pharma
- Website: http://www.acaciapharma.com

## Sources

- Official website: http://www.acaciapharma.com
- ClinicalTrials.gov: trials led by Acacia Pharma Ltd: https://clinicaltrials.gov/search?lead=Acacia%20Pharma%20Ltd
- Wikidata: https://www.wikidata.org/wiki/Q30268747

## Connected records

- fronts: [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- technologies: [Antiemetics for chemotherapy-induced nausea and vomiting](https://onco.cc/technologies/antiemetic-therapy/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/acacia-pharma.json